Lung cancer is the second most prevalent cancer and the leading cause of cancer‐related
death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, and …

Objective To compare the efficacy and safety of first line treatments for patients with
advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer …

Background The APPLE trial aimed to evaluate the feasibility of longitudinal plasma
epidermal growth factor receptor (EGFR) T790M monitoring for the best sequencing strategy …

In non-small cell lung cancer (NSCLC) with human epidermal growth factor receptor 2
(HER2) alterations, chemotherapy remains the standard treatment over a decade, due to the …

Lung cancer has been the leading cause of cancer-related deaths worldwide for decades.
Despite the increasing understanding of the underlying disease mechanisms, the prognosis …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths worldwide. Only
a fraction of NSCLC harbor actionable driver mutations and there is an urgent need for …

The therapeutic landscape of lung cancer treatment is changing rapidly, and new data was
presented at the recently concluded American Society of Clinical Oncology 2022 (ASCO22) …

Despite improved methods of diagnosis and the development of different treatments,
mortality from lung cancer remains surprisingly high. Non-small cell lung cancer (NSCLC) …

Cigarette smoking killed about 8 million people every year and promoted non-small cell lung
cancer (NSCLC). We investigated the molecular mechanism of smoking-promoted NSCLC …

Non-small cell lung cancer (NSCLC) presents the greatest number of identified therapeutic
targets, some of which have therapeutic utility. Currently, detecting EGFR, BRAF, KRAS and …